Physician profile
John M Ford
NPI 1174567572
$2,608.49
in general payments reported to CMS, 2019-2025
26 companies · $360 in 2025
The $360 reported for 2025 was more than what a typical Family Medicine provider received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $289 · 2020: $327 · 2021: $568 · 2022: $292 · 2023: $131 · 2024: $642 · 2025: $360.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,133.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,133.12 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $529.48 | 2019-2025 | Rybelsus, Ozempic |
| Astrazeneca Pharmaceuticals Lp | $439.93 | 2020-2025 | Breztri, Airsupra, Farxiga |
| Sanofi-Aventis U.S. LLC | $222.04 | 2019-2022 | |
| Abbvie INC. | $192.15 | 2019-2024 | |
| Lilly USA, LLC | $179.47 | 2019-2025 | Mounjaro |
| Abiomed | $117.67 | 2024 | Impella |
| Janssen Pharmaceuticals, INC | $105.27 | 2019-2021 | |
| Laborie Medical Technologies Corp. | $104.63 | 2024 | Optilume Bph Drug Coated Balloon Catheter |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $101.66 | 2020-2025 | Xifaxan |
| Merck Sharp & Dohme LLC | $101.10 | 2020-2022 | |
| Astellas Pharma US INC | $85.81 | 2022-2024 | Veozah, Myrbetriq |
| Novartis Pharmaceuticals Corporation | $78.43 | 2019-2022 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $69.46 | 2020-2022 | |
| Glaxosmithkline, LLC. | $50.15 | 2019-2022 | |
| Genentech USA, INC. | $48.93 | 2020-2021 |
Show all 26 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amgen INC. | $40.46 | 2019-2020 | |
| Abbott Laboratories | $24.72 | 2024 | Freestyle Libre 3 |
| Phathom Pharmaceuticals, INC. | $19.49 | 2024 | Voquezna |
| Xeris Pharmaceuticals, INC. | $16.87 | 2024 | Gvoke Hypopen |
| Philips North America LLC | $15.33 | 2024 | (5044) Mcot |
| Exact Sciences Corporation | $13.35 | 2023 | Cologuard Collection Kit |
| Takeda Pharmaceuticals U.S.A., INC. | $12.63 | 2019 | |
| Pacira Therapeutics, INC. | $12.34 | 2020 | |
| Pfizer INC. | $11.71 | 2022 | |
| Allergan, INC. | $11.40 | 2019 | |
| Organon LLC | $4.01 | 2025 | Vtama |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw John Ford listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.